Laurence Matthew Skelton Sells 1,582 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Laurence Matthew Skelton sold 1,582 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $66,412.36. Following the completion of the transaction, the insider directly owned 64,218 shares of the company’s stock, valued at approximately $2,695,871.64. The trade was a 2.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $42.35 on Friday. The firm’s fifty day moving average price is $46.53 and its two-hundred day moving average price is $35.35. The stock has a market cap of $2.97 billion, a PE ratio of -10.61 and a beta of 1.16. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the prior year, the company posted ($0.72) earnings per share. On average, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: FDA priority review and NEJM/ASN recognition for atacicept — Vera reported positive Phase 3 ORIGIN‑3 data for atacicept in IgA nephropathy that were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA has granted priority review for the atacicept BLA with a PDUFA date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid‑2026. Management also said recent 2025 equity and debt financings leave the company well‑capitalized into and beyond approval and launch. Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
• Neutral Sentiment: Financials/earnings update — Vera released FY‑2025 results and quarterly EPS figures; one report shows EPS of ($1.39) for the quarter (slightly missing consensus by ~$0.05). The results highlight continued operating losses but the company emphasizes runway provided by recent financings. Investors will focus on how close the company is to commercialization economics once/if atacicept is approved. View Press Release
• Negative Sentiment: Concentrated insider selling — multiple senior executives (including the CEO, CFO, COO and other officers) sold shares on Feb 23 at roughly $42/share (CEO Marshall Fordyce sold ~16,925 shares; other officers also reduced holdings). Such clustered insider sales can prompt investor caution and short‑term selling pressure despite the regulatory progress. Vera Therapeutics Insider Sells

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Optimize Financial Inc boosted its position in shares of Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Vera Therapeutics by 5.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after buying an additional 290 shares in the last quarter. Intech Investment Management LLC raised its position in Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after buying an additional 424 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VERA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Bank of America boosted their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, Wedbush increased their price target on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $78.80.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.